Prantesh Jain

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (16)

• Corrigendum to 'Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States': [ESMO Open Volume 6, Issue 5, October 2021, 100252].
  ESMO open 2021 DOI: 10.1016/j.esmoop.2021.100286
  +Save
• Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
  ESMO open 2021 DOI: 10.1016/j.esmoop.2021.100252
  +Save
• Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020 DOI: 10.1016/j.bbmt.2020.08.036
  +Save
• Association between myocarditis and other immune-related adverse events secondary to immune checkpoint inhibitor use
  International Journal of Cancer 2020 DOI: 10.1002/IJC.32960
  +Save
• Collagenous Colitis Is Associated With HLA Signature and Shares Genetic Risks With Other Immune-Mediated Diseases
  Gastroenterology 2020 DOI: 10.1053/J.GASTRO.2020.04.063
  +Save
• Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting
  Research and Practice in Thrombosis and Haemostasis 2019 DOI: 10.1002/rth2.12176
  +Save
• Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features
  Lung Cancer 2019 DOI: 10.1016/j.lungcan.2019.06.020
  +Save
• Combination of CT derived radiomic features and lymphovascular invasion status to predict disease recurrence following trimodality therapy in non-small cell lung cancer.
  Journal of Clinical Oncology 2018 DOI: 10.1200/jco.2018.36.15_suppl.e24314
  +Save
• Role of immune-checkpoint inhibitors in lung cancer
  Therapeutic Advances in Respiratory Disease 2018 DOI: 10.1177/1753465817750075
  +Save
• Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
  Clinical Lung Cancer 2018 DOI: 10.1016/j.cllc.2018.01.002
  +Save
• Efficacy of PD-1/PD-L1 inhibitors in the front-line setting as compared to previously treated patients.
  Journal of Clinical Oncology 2017 DOI: 10.1200/jco.2017.35.15_suppl.e20646
  +Save
• Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials.
  Journal of Clinical Oncology 2017 DOI: 10.1200/jco.2017.35.15_suppl.e20647
  +Save
• Isolated Zinc Deficiency Causing Severe Microcytosis and Sideroblastic Anemia
  Turkish Journal of Hematology 2014 DOI: 10.4274/tjh.2012.0145
  +Save
• Afatinib and lung cancer
  Expert Review of Anticancer Therapy 2014 DOI: 10.1586/14737140.2014.983083
  +Save
• 5-flourouracil (5FU) shortage: Clinical implications and costs in a single month.
  Journal of Clinical Oncology 2012 DOI: 10.1200/jco.2012.30.4_suppl.663
  +Save
• A retrospective analysis of all non-AIDS defining cancers (NADC): A subset analysis of the County Hospital AIDS Malignancy Project (CHAMP)
  +Save